Thought Leadership

Latest Report


Biopharma and Medtech Half-Year Review 2021

Despite the continuing pandemic, the biopharma sector saw a return to relative stability during the first half of 2021. Remote operations are proving effective, deals are being made, and clinical research has resumed in many areas. Compared to the same period in 2020, the medtech industry has witnessed a reversal of fortunes. Those producing…

Report library